vatalanib has been researched along with Melanoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J | 1 |
| Basu, B; Biswas, S; Cook, N; Corrie, PG; Kareclas, P; Lomas, D; Mander, AP; Mann, C; Middleton, M; Morgan, B; Nicholson, S; Palmer, C; Sirohi, B; Thomas, A | 1 |
| Kiziltepe, T; Sasisekharan, R; Sengupta, S | 1 |
| Allegrini, PR; Baumann, D; Becquet, M; Brecht, K; Brueggen, J; Ferretti, S; McSheehy, PM; Rausch, M; Rudin, M; Schaeffer, F; Schnell, C; Wood, J | 1 |
1 trial(s) available for vatalanib and Melanoma
| Article | Year |
|---|---|
A phase 2 study of vatalanib in metastatic melanoma patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Phthalazines; Pyridines; Skin Neoplasms; Treatment Outcome; Young Adult | 2010 |
3 other study(ies) available for vatalanib and Melanoma
| Article | Year |
|---|---|
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor | 2002 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Contrast Media; Female; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor A | 2005 |